A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

Edward Pan, Daohai Yu, Binglin Yue, Lisa Potthast, Sajeel Chowdhary, Pamela Smith, Marc Chamberlain

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors, was evaluated for treatment of patients with recurrent glioblastoma (GB) and anaplastic astrocytoma (AA). Fourteen AA and 16 GB patients, all previously treated with surgery, radiotherapy, and temozolomide, were enrolled in a prospective phase II study at either first or second relapse. Patients were treated with daily sunitinib for 4 consecutive weeks, followed by a 2-week break. For AA patients, the most common side effects were fatigue (86 %), diarrhea (43 %), hand-foot syndrome (36 %), neutropenia (36 %), thrombocytopenia (36 %), and nausea (29 %). In the GB cohort, the most common side effects were fatigue (56 %), diarrhea (44 %), neutropenia (31 %), and thrombocytopenia (25 %). Six of 14 (43 %) AA and 5 of 16 (31 %) GB patients experienced grade 3 or greater toxicities. Five patients discontinued study due to drug toxicities. There were no partial or complete responses in either cohort; 8/14 (57 %) AA and 5/16 (31 %) GB patients had stable disease at the first planned assessment. Progression-free survival at 6 months was 21.5 % (AA) and 16.7 % (GB). Median overall survival was 12.1 months (AA) and 12.6 months (GB). These results are comparable to those reported in the literature in patients treated with standard cytotoxic therapies. This is the largest reported trial of sunitinib in recurrent malignant astrocytic gliomas to date, as well as contains the largest AA cohort. Nonetheless, sunitinib did not demonstrate significant anti-glioma activity in patients with recurrent malignant astrocytic gliomas.

Original languageEnglish (US)
Pages (from-to)111-118
Number of pages8
JournalJournal of Neuro-Oncology
Volume110
Issue number1
DOIs
StatePublished - Oct 2012

Fingerprint

Astrocytoma
Glioma
Glioblastoma
temozolomide
Neutropenia
Thrombocytopenia
Fatigue
Diarrhea
sunitinib
Hand-Foot Syndrome
Receptor Protein-Tyrosine Kinases
Drug-Related Side Effects and Adverse Reactions
Nausea
Disease-Free Survival
Radiotherapy
Recurrence
Survival

Keywords

  • Anaplastic astrocytoma
  • Glioblastoma
  • Prospective trial
  • Recurrent malignant glioma
  • Sunitinib

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. / Pan, Edward; Yu, Daohai; Yue, Binglin; Potthast, Lisa; Chowdhary, Sajeel; Smith, Pamela; Chamberlain, Marc.

In: Journal of Neuro-Oncology, Vol. 110, No. 1, 10.2012, p. 111-118.

Research output: Contribution to journalArticle

Pan, E, Yu, D, Yue, B, Potthast, L, Chowdhary, S, Smith, P & Chamberlain, M 2012, 'A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma', Journal of Neuro-Oncology, vol. 110, no. 1, pp. 111-118. https://doi.org/10.1007/s11060-012-0943-z
Pan, Edward ; Yu, Daohai ; Yue, Binglin ; Potthast, Lisa ; Chowdhary, Sajeel ; Smith, Pamela ; Chamberlain, Marc. / A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. In: Journal of Neuro-Oncology. 2012 ; Vol. 110, No. 1. pp. 111-118.
@article{fd693517bbc84f42b1543f8f9c9b275f,
title = "A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma",
abstract = "Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors, was evaluated for treatment of patients with recurrent glioblastoma (GB) and anaplastic astrocytoma (AA). Fourteen AA and 16 GB patients, all previously treated with surgery, radiotherapy, and temozolomide, were enrolled in a prospective phase II study at either first or second relapse. Patients were treated with daily sunitinib for 4 consecutive weeks, followed by a 2-week break. For AA patients, the most common side effects were fatigue (86 {\%}), diarrhea (43 {\%}), hand-foot syndrome (36 {\%}), neutropenia (36 {\%}), thrombocytopenia (36 {\%}), and nausea (29 {\%}). In the GB cohort, the most common side effects were fatigue (56 {\%}), diarrhea (44 {\%}), neutropenia (31 {\%}), and thrombocytopenia (25 {\%}). Six of 14 (43 {\%}) AA and 5 of 16 (31 {\%}) GB patients experienced grade 3 or greater toxicities. Five patients discontinued study due to drug toxicities. There were no partial or complete responses in either cohort; 8/14 (57 {\%}) AA and 5/16 (31 {\%}) GB patients had stable disease at the first planned assessment. Progression-free survival at 6 months was 21.5 {\%} (AA) and 16.7 {\%} (GB). Median overall survival was 12.1 months (AA) and 12.6 months (GB). These results are comparable to those reported in the literature in patients treated with standard cytotoxic therapies. This is the largest reported trial of sunitinib in recurrent malignant astrocytic gliomas to date, as well as contains the largest AA cohort. Nonetheless, sunitinib did not demonstrate significant anti-glioma activity in patients with recurrent malignant astrocytic gliomas.",
keywords = "Anaplastic astrocytoma, Glioblastoma, Prospective trial, Recurrent malignant glioma, Sunitinib",
author = "Edward Pan and Daohai Yu and Binglin Yue and Lisa Potthast and Sajeel Chowdhary and Pamela Smith and Marc Chamberlain",
year = "2012",
month = "10",
doi = "10.1007/s11060-012-0943-z",
language = "English (US)",
volume = "110",
pages = "111--118",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

AU - Pan, Edward

AU - Yu, Daohai

AU - Yue, Binglin

AU - Potthast, Lisa

AU - Chowdhary, Sajeel

AU - Smith, Pamela

AU - Chamberlain, Marc

PY - 2012/10

Y1 - 2012/10

N2 - Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors, was evaluated for treatment of patients with recurrent glioblastoma (GB) and anaplastic astrocytoma (AA). Fourteen AA and 16 GB patients, all previously treated with surgery, radiotherapy, and temozolomide, were enrolled in a prospective phase II study at either first or second relapse. Patients were treated with daily sunitinib for 4 consecutive weeks, followed by a 2-week break. For AA patients, the most common side effects were fatigue (86 %), diarrhea (43 %), hand-foot syndrome (36 %), neutropenia (36 %), thrombocytopenia (36 %), and nausea (29 %). In the GB cohort, the most common side effects were fatigue (56 %), diarrhea (44 %), neutropenia (31 %), and thrombocytopenia (25 %). Six of 14 (43 %) AA and 5 of 16 (31 %) GB patients experienced grade 3 or greater toxicities. Five patients discontinued study due to drug toxicities. There were no partial or complete responses in either cohort; 8/14 (57 %) AA and 5/16 (31 %) GB patients had stable disease at the first planned assessment. Progression-free survival at 6 months was 21.5 % (AA) and 16.7 % (GB). Median overall survival was 12.1 months (AA) and 12.6 months (GB). These results are comparable to those reported in the literature in patients treated with standard cytotoxic therapies. This is the largest reported trial of sunitinib in recurrent malignant astrocytic gliomas to date, as well as contains the largest AA cohort. Nonetheless, sunitinib did not demonstrate significant anti-glioma activity in patients with recurrent malignant astrocytic gliomas.

AB - Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors, was evaluated for treatment of patients with recurrent glioblastoma (GB) and anaplastic astrocytoma (AA). Fourteen AA and 16 GB patients, all previously treated with surgery, radiotherapy, and temozolomide, were enrolled in a prospective phase II study at either first or second relapse. Patients were treated with daily sunitinib for 4 consecutive weeks, followed by a 2-week break. For AA patients, the most common side effects were fatigue (86 %), diarrhea (43 %), hand-foot syndrome (36 %), neutropenia (36 %), thrombocytopenia (36 %), and nausea (29 %). In the GB cohort, the most common side effects were fatigue (56 %), diarrhea (44 %), neutropenia (31 %), and thrombocytopenia (25 %). Six of 14 (43 %) AA and 5 of 16 (31 %) GB patients experienced grade 3 or greater toxicities. Five patients discontinued study due to drug toxicities. There were no partial or complete responses in either cohort; 8/14 (57 %) AA and 5/16 (31 %) GB patients had stable disease at the first planned assessment. Progression-free survival at 6 months was 21.5 % (AA) and 16.7 % (GB). Median overall survival was 12.1 months (AA) and 12.6 months (GB). These results are comparable to those reported in the literature in patients treated with standard cytotoxic therapies. This is the largest reported trial of sunitinib in recurrent malignant astrocytic gliomas to date, as well as contains the largest AA cohort. Nonetheless, sunitinib did not demonstrate significant anti-glioma activity in patients with recurrent malignant astrocytic gliomas.

KW - Anaplastic astrocytoma

KW - Glioblastoma

KW - Prospective trial

KW - Recurrent malignant glioma

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84866364645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866364645&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0943-z

DO - 10.1007/s11060-012-0943-z

M3 - Article

VL - 110

SP - 111

EP - 118

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -